Prof Salomon Manier speaks to ecancer about the IFM2017-03 phase 3 trial.

This trial investigates a dexamethasone-sparing regimen with daratumumab and lenalidomide for frail patients with newly diagnosed multiple myeloma.

The trial shows significant benefits in progression-free survival and overall survival for the daratumumab group, with participants averaging 81 years old.

The safety profile indicates manageable side effects and no increase in treatment discontinuation, highlighting the importance of tailored treatment strategies for elderly patients.